[
  {
    "ts": null,
    "headline": "Genmab raises full-year outlook, shares rise",
    "summary": "Investing.com -- Genmab raised its full-year revenue and profit guidance on Thursday, driven by stronger-than-expected royalties from key partner drugs.",
    "url": "https://finnhub.io/api/news?id=479680a0c71618a0997680d2f2495e0fd6d78bdc9adfd392c4720d3c238d2939",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754585315,
      "headline": "Genmab raises full-year outlook, shares rise",
      "id": 136266436,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Investing.com -- Genmab raised its full-year revenue and profit guidance on Thursday, driven by stronger-than-expected royalties from key partner drugs.",
      "url": "https://finnhub.io/api/news?id=479680a0c71618a0997680d2f2495e0fd6d78bdc9adfd392c4720d3c238d2939"
    }
  },
  {
    "ts": null,
    "headline": "Is Encompass Health (EHC) Outperforming Other Medical Stocks This Year?",
    "summary": "Here is how Encompass Health (EHC) and Johnson & Johnson (JNJ) have performed compared to their sector so far this year.",
    "url": "https://finnhub.io/api/news?id=d57ff8fcf81e6dfb3cb447f1a69a04455bf279b4a638c372a82a56f5395db41c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754574002,
      "headline": "Is Encompass Health (EHC) Outperforming Other Medical Stocks This Year?",
      "id": 136266437,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Here is how Encompass Health (EHC) and Johnson & Johnson (JNJ) have performed compared to their sector so far this year.",
      "url": "https://finnhub.io/api/news?id=d57ff8fcf81e6dfb3cb447f1a69a04455bf279b4a638c372a82a56f5395db41c"
    }
  },
  {
    "ts": null,
    "headline": "United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda",
    "summary": "The United States Pharmaceutical Market is projected to reach $979.25 billion by 2033, from $638.86 billion in 2024, at a CAGR of 4.86% (2025-2033). Growth is driven by rising chronic diseases, demand for innovative medicines, and advanced biotech solutions. High R&D investments in oncology, neurology, and infectious diseases fuel the market, alongside robust government support and insurance coverage. California and New York lead in R&D and distribution. Key challenges include regulatory complex",
    "url": "https://finnhub.io/api/news?id=c5faab32289036b61d1de41f603a0cb2c73c4612692dcf7386f42a8f151806d8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754570460,
      "headline": "United States Pharmaceutical Market Forecast and Company Analysis Report 2025-2033 Featuring F. Hoffmann-La Roche, Novartis, Abbvie, Johnson & Johnson, Merck, Pfizer, BMS, Sanofi, GSK, Takeda",
      "id": 136246157,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The United States Pharmaceutical Market is projected to reach $979.25 billion by 2033, from $638.86 billion in 2024, at a CAGR of 4.86% (2025-2033). Growth is driven by rising chronic diseases, demand for innovative medicines, and advanced biotech solutions. High R&D investments in oncology, neurology, and infectious diseases fuel the market, alongside robust government support and insurance coverage. California and New York lead in R&D and distribution. Key challenges include regulatory complex",
      "url": "https://finnhub.io/api/news?id=c5faab32289036b61d1de41f603a0cb2c73c4612692dcf7386f42a8f151806d8"
    }
  },
  {
    "ts": null,
    "headline": "Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical",
    "summary": "The Saudi Arabia OTC Artificial Tears Market is projected to reach USD 79.09 million by 2033, growing at a CAGR of 4.22% from 2025. Contributing factors include a rising elderly population, increased incidence of dry eye syndrome, and greater use of digital screens. Enhanced awareness of eye health, expanding retail and online pharmacies, and favorable healthcare policies are also promoting market growth. Non-prescription artificial tears offer convenient solutions for mild to moderate condition",
    "url": "https://finnhub.io/api/news?id=09e8791d380db68c19a93903274690cc09b7fe501a69fed3d31134b08af60fcd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754569860,
      "headline": "Saudi Arabia OTC Artificial Tears Market Forecast and Company Analysis Report 2025-2033 Featuring AbbVie, Akorn, Alcon, Bausch Health, J&J, Nicox, Novartis, Santen Pharmaceutical, Sun Pharmaceutical",
      "id": 136246158,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Saudi Arabia OTC Artificial Tears Market is projected to reach USD 79.09 million by 2033, growing at a CAGR of 4.22% from 2025. Contributing factors include a rising elderly population, increased incidence of dry eye syndrome, and greater use of digital screens. Enhanced awareness of eye health, expanding retail and online pharmacies, and favorable healthcare policies are also promoting market growth. Non-prescription artificial tears offer convenient solutions for mild to moderate condition",
      "url": "https://finnhub.io/api/news?id=09e8791d380db68c19a93903274690cc09b7fe501a69fed3d31134b08af60fcd"
    }
  },
  {
    "ts": null,
    "headline": "August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys",
    "summary": "Discover the top Dow dividend stocks for steady gains by 2026.",
    "url": "https://finnhub.io/api/news?id=5b4324cf7aa0db1844e537f7ec31acf7b22ccb8eb46fc4995dc453357313aa09",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754569431,
      "headline": "August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys",
      "id": 136249581,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/481098702/image_481098702.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover the top Dow dividend stocks for steady gains by 2026.",
      "url": "https://finnhub.io/api/news?id=5b4324cf7aa0db1844e537f7ec31acf7b22ccb8eb46fc4995dc453357313aa09"
    }
  },
  {
    "ts": null,
    "headline": "Kenvue forecasts annual profit below estimates amid strategic review",
    "summary": "Wall Street analysts view the Band-Aid maker as an acquisition target after it came under pressure from investors, who have criticized the lackluster performance in its skin health and beauty segment that houses brands such as Neutrogena and Aveeno.  Kenvue in July ousted its CEO Thibaut Mongon and named Kirk Perry as an interim chief, and had then said it created a committee to weigh portfolio simplification and potential divestitures.",
    "url": "https://finnhub.io/api/news?id=47978309d1c4f1b12f46b3a20d9d949abe5fc8590d6e0af111ba38ef09337b3b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754564118,
      "headline": "Kenvue forecasts annual profit below estimates amid strategic review",
      "id": 136246725,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Wall Street analysts view the Band-Aid maker as an acquisition target after it came under pressure from investors, who have criticized the lackluster performance in its skin health and beauty segment that houses brands such as Neutrogena and Aveeno.  Kenvue in July ousted its CEO Thibaut Mongon and named Kirk Perry as an interim chief, and had then said it created a committee to weigh portfolio simplification and potential divestitures.",
      "url": "https://finnhub.io/api/news?id=47978309d1c4f1b12f46b3a20d9d949abe5fc8590d6e0af111ba38ef09337b3b"
    }
  }
]